Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 19, Issue 4, Pages 614-623Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161213804581954
Keywords
Sirtuin modulators; cancer; drug design; epigenetics; drug discovery
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [6108, 6266]
- European Seventh Framework Program [256986, PANACREAS]
- University of Genova
Ask authors/readers for more resources
Sirtuins are a family of NAD(+)-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available